|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01EX19
|
|
gptkbp:brand
|
gptkb:Retevmo
|
|
gptkbp:CASNumber
|
2152628-33-4
|
|
gptkbp:chemicalClass
|
small molecule
|
|
gptkbp:developer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:hasMolecularFormula
|
C29H31N7O3
|
|
gptkbp:hasSMILES
|
CC1=CC2=C(C=C1)N=C(N2)N3CCN(CC3)CC4=CC=C(C=C4)C(=O)NC5=CC=CC=C5C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Selpercatinib
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits RET kinase activity
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297598
gptkb:DB15685
121694966
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
hypertension
QT prolongation
hepatotoxicity
|
|
gptkbp:target
|
gptkb:RET_proto-oncogene
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:RET_fusion-positive_thyroid_cancer
medullary thyroid cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|